The 80th Annual Meeting of the Japanese Society of Hematology

Session information

Print

Oral Session

Oral Session 3-11B AML: FLT3 mutations

Sun. Oct 14, 2018 9:40 AM - 10:40 AM No.11 (Osaka International Convention Center, 10F 1004-5)

Chair: Norio Asou (Department of Hematology, International Medical Center, Saitama Medical University, Japan)

[OS3-11B-1] Prognostic impact of acute myeloid leukemia with low allelic ratio FLT3-ITD and NPM1 mutation

Nana Nakajima1, Masahiro Sakaguchi1, Yuho Najima2, Kensuke Usuki3, Toshimitsu Ueki4, Iekuni Oh5, Sinichiro Mori6, Eri Kawata7, Nobuhiko Uoshima7, Yutaka Kobayashi7, Shinichi Kako8, Kenji Tajika9, Seiji Gomi9, Katsuhiro Shono10, Kensuke Kayamori11, Masao Hagihara12, Junya Kanda13, Hitoji Uchiyama14, Junya Kuroda15, Naoyuki Uchida16, Yasushi Kubota17, Shinya Kimura17, Saiko Kurosawa18, Kunihito Arai1, Kazuhiko Kakihana2, Yoshinobu Kanda5,8, Kazuteru Ohashi2, Takahiro Fukuda18, Hiroki Yamaguchi1, Koiti Inokuchi1 (1.Department of Hematology, Nippon Medical School, Tokyo, Japan, 2.Hematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, 3.Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan, 4.Department of Hematology, Nagano Red Cross Hospital, Nagano, Japan, 5.Division of Hematology, Jichi Medical University, Tochigi, Japan, 6.Hemato-Oncology Department, St Lukes International Hospital, Tokyo, Japan, 7.Hematology Division, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan, 8.Hematology Division, Saitama Medical Center, Jichi Medical University, Saitama, Japan, 9.Department of Hematology, Yokohama Minami Kyousai Hospital, Kanagawa, Japan, 10.Department of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan, 11.Department of Hematology, Chiba University Hospital, Chiba, Japan, 12.Department of Hematology, Eiju General Hopital, Tokyo, Japan, 13.Department of Hematology and Oncology, Kyoto University, Kyoto, Japan., 14.Hematology Division, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, 15.Hematology-and-Oncology Division, Kyoto Prefectural University of Medicine, Kyoto, Japan, 16.Department of Hematology, Toranomon Hospital, Tokyo, Japan, 17.Division of Hematology, Respiratory Medicine and Oncology,Saga University, Saga, Japan, 18.Department of HSCT, National Cancer Center Hospital, Tokyo, Japan)

[OS3-11B-3] The clinical features and prognostic impact of acute myeloid leukemia with FLT3-TKD mutation

Marika Kuboyama1, Masahiro Sakaguchi1, Yuho Najima2, Kensuke Usuki3, Toshimitsu Ueki4, Iekuni Oh5, Sinichiro Mori6, Eri Kawata7, Nobuhiko Uoshima7, Yutaka Kobayashi7, Shinichi Kako8, Kenji Tajika9, Seiji Gomi9, Katsuhiro Shono10, Kensuke Kayamori11, Masao Hagihara12, Junya Kanda13, Hitoji Uchiyama14, Junya Kuroda15, Naoyuki Uchida16, Shinya Kimura17, Saiko Kurosawa18, Kenta Date1, Satoshi Wakita1, Kazuhiko Kakihana2, Yoshinobu Kanda5,8, Takahiro Fukuda18, Kazuteru Ohashi2, Hiroki Yamaguchi1, Koiti Inokuchi1 (1.Department of Hematology, Nippon Medical School, Tokyo, Japan, 2.Hematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, 3.Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan, 4.Department of Hematology, Nagano Red Cross Hospital, Nagano, Japan, 5.Division of Hematology, Jichi Medical University, Tochigi, Japan, 6.Hemato-Oncology Department, St Lukes International Hospital, Tokyo, Japan, 7.Hematology Division, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan, 8.Hematology Division, Saitama Medical Center, Jichi Medical University, Saitama, Japan, 9.Department of Hematology, Yokohama Minami Kyousai Hospital, Kanagawa, Japan, 10.Department of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan, 11.Department of Hematology, Chiba University Hospital, Chiba, Japan, 12.Department of Hematology, Eiju General Hopital, Tokyo, Japan, 13.Department of Hematology and Oncology, Kyoto University, Kyoto, Japan., 14.Hematology Division, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, 15.Hematology-and-Oncology Division, Kyoto Prefectural University of Medicine, Kyoto, Japan, 16.Department of Hematology, Toranomon Hospital, Tokyo, Japan, 17.Division of Hematology, Respiratory Medicine and Oncology,Saga University, Saga, Japan, 18.Department of HSCT, National Cancer Center Hospital, Tokyo, Japan)

[OS3-11B-5] Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed/refractory AML

Kensuke Usuki1, Hiroshi Handa2, Ilseung Choi3, Takahiro Yamauchi4, Hiroatsu Iida5, Tomoko Hata6, Shoichi Ohwada7, Noriko Okudaira7, Kota Nakamura7, Sakura Sakajiri8 (1.NTT Medical Center Tokyo, Tokyo, Japan, 2.Gunma University Hospital, Maebashi, Japan, 3.National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 4.University of Fukui Hospital, Fukui, Japan, 5.National Hospital Organization Nagoya Medical Center, Aichi, Japan, 6.Nagasaki University Hospital, Nagasaki, Japan, 7.Daiichi Sankyo Co., Ltd., Tokyo, Japan, 8.Juntendo University Urayasu Hospital, Urayasu, Japan)

[OS3-11B-6] Phase 2 results of quizartinib in Japanese patients with FLT3-ITD mutated relapsed/refractory AML

Takeshi Takahashi1, Kensuke Usuki2, Kosei Matsue3, Hitoshi Ohno4, Toru Sakura5, Ryota Imanaka6, Masato Murakami7, Shoichi Ohwada7, Taiga Takagi7, Sakura Sakajiri8 (1.Gifu Municipal Hospital, Gifu, Japan, 2.NTT Medical Center Tokyo, Tokyo, Japan, 3.Kameda Medical Center, Kamogawa, Japan, 4.Tenri Hospital, Tenri, Japan, 5.Saiseikai Maebashi Hospital, Maebashi, Japan, 6.Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan, 7.Daiichi Sankyo Co., Ltd., Tokyo, Japan, 8.Juntendo University Urayasu Hospital, Urayasu, Japan)